Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Seretide Diskus is easy to use and preferred by patients1
Seretide Diskus is easy to use and preferred by patients1
*The DISKUS inhaler scored significantly better than the Turbohaler for perceived ease of use, hygiene, shape, weight, knowing how many doses were left, the presence of an attached cover, and attractiveness1
Fewer handling errors when using diskus compared to other devices2
This graph has been independently created by GSK from the original data. The same results were first published in Khassawneh BY, et al. Respir Care 2008;53:324-328. *When compared to Aerolizer (p=0.031), Turbohaler (p<0.001) and MDI (p<0.001). Aerolizer is a registered trademark of the Novartis group of companies. Turbohaler is a trademark of the AstraZeneca group of companies.
SERETIDE OFFERS FLEXIBILITY WHEN CHOOSING A DEVICE3
1-individual dose counter3
2-pre-filled blister ensuring dose consistency3
3-delivers consistent dosing even for patients with low inspiratory flow rate(minimum 30L/min)4
The lowest incorrect handling compared with the Aerolizer, Turbohaler and MDI devices: 6.8% vs 16.9%,43.2% and 74,6%,respectively2
DISKUS IS EASY TO USE AND PREFERRED BY 65% OF PATIENTS1
Seretide safety information:
Contraindications:
SERETIDE is contraindicated in patients with a history of hypersensitivity to any of the ingredients(For SERETIDE DISKUS is contraindicated in patients with severe milk-protein allergy.
Adverse events:
Very common: Headache
Common: Candidiasis of mouth and throat, pneumonia(in COPD patients), Hoarseness/dysphonia, Muscle cramps, arthralgia.
Abbreviation:
MDI, metered-dose inhalers
References:
[1] Schlaeppi M, et al, Brit J Clin Pract 1996;50:14-19.
[2] Khassawneh BY, et al. Respir Care 2008;53:324-328.
[3] Shapiro G, et al. Am J Respir Crit Care Med 2000;161:527–534.
[4] Nielsen KG; European Respiratory Journal 1998 11(2): 350-354.
[5] Seretide Diskus local prescribing information based on GDS37/IP122.
GSK is not responsible for third party content.
SINA Guidelines
Asthma Control Test
Seretide Prescribing Information
Trademarks are owned by or licensed to the GSK group of companies
PM-SA-FPS-WCNT-250001 - Date of preparation: May 2025
